Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study. I

Phase 2

Sun Pharma Global FZE